NASDAQ: RPRXRoyalty Pharma PLC Stock
$33.41+0.39 (+1.18%)
Updated Mar 18, 2025
RPRX Price
$33.41
Fair Value Price
$25.89
Market Cap
$19.26B
52 Week Low
$24.05
52 Week High
$34.20
P/E
17.4x
P/B
1.86x
P/S
5.05x
PEG
0.31x
Dividend Yield
1.29%
Revenue
$2.26B
Earnings
$858.98M
Gross Margin
100%
Operating Margin
47.91%
Profit Margin
37.9%
Debt to Equity
0.76
Operating Cash Flow
$3B
Beta
0.55
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
RPRX Overview
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RPRX's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
RPRX
Ranked#28 of 482
Ranked#28 of 482
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.35 | A | |
| $139.51 | A | |
| $7.87 | A |
Be the first to know about important RPRX news, forecast changes, insider trades & much more!
RPRX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RPRX scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RPRX ($33.41) is overvalued by 29.02% relative to our estimate of its Fair Value price of $25.89 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
RPRX ($33.41) is not significantly undervalued (29.02%) relative to our estimate of its Fair Value price of $25.89 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RPRX ($33.41) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more RPRX due diligence checks available for Premium users.
Valuation
RPRX fair value
Fair Value of RPRX stock based on Discounted Cash Flow (DCF)
Price
$33.41
Fair Value
$25.89
Overvalued by
29.02%
RPRX ($33.41) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RPRX ($33.41) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RPRX ($33.41) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RPRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
17.4x
Industry
-110.15x
Market
30.9x
RPRX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
RPRX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
RPRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.86x
Industry
4.74x
RPRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RPRX price to earnings growth (PEG)
For valuing profitable companies with growth potential
RPRX is good value based... subscribe to Premium to read more.
PEG Value Valuation
RPRX's financial health
Profit margin
Revenue
$593.6M
Net Income
$208.2M
Profit Margin
35.1%
RPRX's Earnings (EBIT) of $1.08B... subscribe to Premium to read more.
Interest Coverage Financials
RPRX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$18.2B
Liabilities
$7.9B
Debt to equity
0.76
RPRX's short-term assets ($1.80B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RPRX's long-term liabilities ($6.63B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RPRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RPRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$742.5M
Investing
-$505.6M
Financing
-$258.0M
RPRX's operating cash flow ($2.77B)... subscribe to Premium to read more.
Debt Coverage Financials
RPRX vs Biotech Stocks
Royalty Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.